Berlin-based Mayd, which offers rapid pharmacy deliveries, raises a €30M Series A led by Lightspeed, following a €13M seed in October 2021
Berlin-based Mayd, a startup that's building an on-demand medicine delivery platform in Europe, has fast followed a chunky seed raise last fall …
Context & Ripple Effects
Mayd is moving fast through the funding ladder: barely three months after its October 2021 seed round, the Berlin startup has closed a €30M Series A led by Lightspeed to scale its under-30-minute medicine delivery model built on small local pharmacies. The compressed timeline signals that investors see rapid pharmacy delivery as a category worth accelerating before rivals entrench.
The round also fits a broader Berlin health-tech funding run visible in the related coverage — Amboss's earlier €30M Series B for its medical knowledge platform, Temedica's pharma-data raise, and later large rounds for clinic operator Patient21 and practice-software firm Nelly — with Mayd now the logistics layer of that stack.
First-order effects
- Lightspeed's €30M gives Mayd the runway to expand its courier network and sign more small pharmacies onto its platform, directly widening the set of pharmacies that can offer sub-30-minute delivery without building their own logistics.
- For Lightspeed, this is an early-stage healthcare bet in Europe layered on top of a portfolio increasingly weighted toward large AI positions like Anthropic, xAI, and Mistral.
Second-order effects
- Competing on-demand pharmacy players in Germany and wider Europe now face a better-capitalized Mayd, forcing them to either raise at pace or differentiate on coverage, pricing, or pharmacy relationships rather than speed alone.
- Small partner pharmacies gain volume but also begin ceding customer data and last-mile economics to a platform intermediary — the same dependency dynamic seen across Berlin health startups serving practitioners and pharma companies.
Third-order effects
- If the funding cadence holds across the Berlin cohort — delivery (Mayd), data (Temedica), clinics (Patient21), practice SaaS (Nelly) — European healthcare is structurally re-layering into venture-backed platforms that sit between patients, pharmacies, and payers, with regulators eventually forced to define rules for who may intermediate prescription fulfillment.
- Pharmacy retail could follow the grocery pattern where independent stores survive by plugging into aggregator platforms, trading margin for demand they cannot generate alone.
The trend: European health-tech is absorbing ever-larger venture rounds as startups digitize each link in the pharmacy-to-patient chain, with Berlin emerging as the hub for that build-out.